Fundación Pública Andaluza para la Gestión de la investigación en salud de Sevilla (FISEVI)
Welcome,         Profile    Billing    Logout  
 3 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Romero-Gomez, Manuel
NCT04710524 / 2020-005187-63: FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

Recruiting
2a
60
Europe
Placebo, FM101 150 mg BID, FM101 300 mg BID
Future Medicine
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
05/23
08/23
NCT04442334: The European NAFLD Registry

Recruiting
N/A
10000
Europe
Newcastle University, Newcastle-upon-Tyne Hospitals NHS Trust, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Institute of Cardiometabolism and Nutrition, France, University of Cambridge, Örebro University, Sweden, University of Bern, University of Oxford, University of Turin, Italy, University of Angers, University Hospital, Antwerp, Linkoeping University, University of Helsinki, UMC Utrecht, National and Kapodistrian University of Athens, University of Lisbon, University of Milan, University of Palermo, Catholic University of the Sacred Heart, Wuerzburg University Hospital, RWTH Aachen University, University of Nottingham, Medical University of Vienna, University of Birmingham, University of Florence, Assistance Publique - Hôpitaux de Paris, University Medical Center Mainz
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver, Hepatocellular Carcinoma, Cardiovascular Diseases, Type 2 Diabetes, Dyslipidaemia, Hypertension, Obesity, Other Associated Comorbidities
12/30
12/30
NCT05479721: LITMUS Imaging Study

Active, not recruiting
N/A
450
Europe, US
University of Oxford, Newcastle University, University of Nottingham, University of Cambridge, University of Seville, Pinnacle Clinical Research, PLLC, ICAN Nutrition Education and Research, Assistance Publique - Hôpitaux de Paris, University of Angers, University of Palermo, University of Turin, Italy, University Medical Center Mainz, University of Helsinki, University of Bern, Linkoeping University, Perspectum, Antaros Medical, Resoundant Inc, Pfizer, Novartis, Takeda, Intercept Pharmaceuticals, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Boehringer Ingelheim
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
10/25
10/25
Ampuero, Javier
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
SPRING, NCT04595825 / 2019-002945-39: CM-101 in PSC Patients -The Study

Active, not recruiting
2
68
Europe, US, RoW
Anti-human CCL24 monoclonal antibody (CM-101), Placebo
ChemomAb Ltd., ChemomAb Ltd
Primary Sclerosing Cholangitis
09/24
09/25
NCT05239858: International Wilson's Disease Patient Registry (iWilson Registry)

Recruiting
N/A
500
Europe, RoW
Orphalan, Ergomed
Wilson's Disease
12/27
12/27
Romero-Gómez, Manuel
NASH-PI, NCT06688149: NASH Patient's Itinerary: Comparison of Strategies for Screening, Referring and Management of Diabetic Patients

Completed
N/A
536
Europe
Derivation algorithms
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Gilead Sciences, Barcelona Institute for Global Health, Harokopio University, University Medical Center Mainz, Universitätsklinikum Düsseldorf
Non-alcoholic Fatty Liver Disease (NAFLD)
01/23
01/24
Insenser, Miriam Ben-Yelun
NCT05546424: EMRESERVA to Enhance Cognitive Reserve in Multiple Sclerosis

Completed
N/A
58
Europe
EMRESERVA
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Cognitive Change
11/23
11/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Romero-Gomez, Manuel
NCT04710524 / 2020-005187-63: FM101 Efficacy Study in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

Recruiting
2a
60
Europe
Placebo, FM101 150 mg BID, FM101 300 mg BID
Future Medicine
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
05/23
08/23
NCT04442334: The European NAFLD Registry

Recruiting
N/A
10000
Europe
Newcastle University, Newcastle-upon-Tyne Hospitals NHS Trust, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Institute of Cardiometabolism and Nutrition, France, University of Cambridge, Örebro University, Sweden, University of Bern, University of Oxford, University of Turin, Italy, University of Angers, University Hospital, Antwerp, Linkoeping University, University of Helsinki, UMC Utrecht, National and Kapodistrian University of Athens, University of Lisbon, University of Milan, University of Palermo, Catholic University of the Sacred Heart, Wuerzburg University Hospital, RWTH Aachen University, University of Nottingham, Medical University of Vienna, University of Birmingham, University of Florence, Assistance Publique - Hôpitaux de Paris, University Medical Center Mainz
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver, Hepatocellular Carcinoma, Cardiovascular Diseases, Type 2 Diabetes, Dyslipidaemia, Hypertension, Obesity, Other Associated Comorbidities
12/30
12/30
NCT05479721: LITMUS Imaging Study

Active, not recruiting
N/A
450
Europe, US
University of Oxford, Newcastle University, University of Nottingham, University of Cambridge, University of Seville, Pinnacle Clinical Research, PLLC, ICAN Nutrition Education and Research, Assistance Publique - Hôpitaux de Paris, University of Angers, University of Palermo, University of Turin, Italy, University Medical Center Mainz, University of Helsinki, University of Bern, Linkoeping University, Perspectum, Antaros Medical, Resoundant Inc, Pfizer, Novartis, Takeda, Intercept Pharmaceuticals, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Boehringer Ingelheim
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
10/25
10/25
Ampuero, Javier
PACIFIC, NCT05525520 / 2021-002526-25: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Completed
2
62
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc, Escient Pharmaceuticals, Inc.
Pruritus
07/24
09/24
SPRING, NCT04595825 / 2019-002945-39: CM-101 in PSC Patients -The Study

Active, not recruiting
2
68
Europe, US, RoW
Anti-human CCL24 monoclonal antibody (CM-101), Placebo
ChemomAb Ltd., ChemomAb Ltd
Primary Sclerosing Cholangitis
09/24
09/25
NCT05239858: International Wilson's Disease Patient Registry (iWilson Registry)

Recruiting
N/A
500
Europe, RoW
Orphalan, Ergomed
Wilson's Disease
12/27
12/27
Romero-Gómez, Manuel
NASH-PI, NCT06688149: NASH Patient's Itinerary: Comparison of Strategies for Screening, Referring and Management of Diabetic Patients

Completed
N/A
536
Europe
Derivation algorithms
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Gilead Sciences, Barcelona Institute for Global Health, Harokopio University, University Medical Center Mainz, Universitätsklinikum Düsseldorf
Non-alcoholic Fatty Liver Disease (NAFLD)
01/23
01/24
Insenser, Miriam Ben-Yelun
NCT05546424: EMRESERVA to Enhance Cognitive Reserve in Multiple Sclerosis

Completed
N/A
58
Europe
EMRESERVA
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Cognitive Change
11/23
11/23

Download Options